Flores et al. show that brain-penetrant eIF2B agonists suppress ISR activation in cellular and mouse models of ALS and reduce ISR biomarkers in humans, enabling further clinical studies of ISR inhibition in individuals with neurological diseases
- Brittany N. Flores
- Seungyoon B. Yu
- Joseph W. Lewcock
